What is HC Wainwright’s Estimate for NRIX FY2027 Earnings?

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Stock analysts at HC Wainwright issued their FY2027 EPS estimates for Nurix Therapeutics in a research note issued to investors on Friday, October 16th. HC Wainwright analyst R. Burns forecasts that the company will earn ($2.42) per share for the year. HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is $1.15 per share.

Several other analysts have also weighed in on the company. Stifel Nicolaus set a $41.00 price objective on Nurix Therapeutics in a report on Tuesday, October 13th. Truist Financial cut their price objective on Nurix Therapeutics from $34.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, October 13th. Royal Bank Of Canada reduced their target price on Nurix Therapeutics from $36.00 to $35.00 and set an “outperform” rating on the stock in a report on Tuesday, October 13th. Wall Street Zen upgraded Nurix Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Mizuho upped their price target on Nurix Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.79.

Nurix Therapeutics Stock Performance

Shares of Nurix Therapeutics stock opened at $24.93 on Monday. The firm has a market cap of $2.72 billion, a PE ratio of 10.79 and a beta of 1.82. The firm’s 50-day simple moving average is $25.09 and its 200-day simple moving average is $21.27. Nurix Therapeutics has a 1 year low of $9.93 and a 1 year high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Monday, October 12th. The company reported $4.73 EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $5.33. The firm had revenue of $673.06 million for the quarter, compared to the consensus estimate of $24.35 million. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 49.34%.

Insider Transactions at Nurix Therapeutics

In related news, CFO Hans van Houte sold 4,761 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the completion of the transaction, the chief financial officer directly owned 40,166 shares in the company, valued at $978,443.76. This represents a 10.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julia P. Gregory sold 22,583 shares of the firm’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $23.40, for a total value of $528,442.20. Following the completion of the sale, the director owned 10,750 shares in the company, valued at $251,550. The trade was a 67.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 45,407 shares of company stock worth $1,083,206. 6.70% of the stock is currently owned by company insiders.

Institutional Trading of Nurix Therapeutics

A number of large investors have recently modified their holdings of the company. Trails Edge Capital Partners LP bought a new position in Nurix Therapeutics in the 2nd quarter worth about $38,166,318. Bank of New York Mellon Corp acquired a new position in shares of Nurix Therapeutics during the second quarter worth approximately $6,614,000. Man Group plc acquired a new position in shares of Nurix Therapeutics during the second quarter worth approximately $2,076,000. Bank of America Corp DE bought a new position in Nurix Therapeutics in the 2nd quarter worth approximately $20,429,000. Finally, Perceptive Advisors LLC grew its holdings in Nurix Therapeutics by 4.4% in the 1st quarter. Perceptive Advisors LLC now owns 3,710,877 shares of the company’s stock worth $57,519,000 after buying an additional 155,000 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.